{"id":"NCT01874145","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Safety and Tolerability of Glatiramer Acetate","officialTitle":"An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06","primaryCompletion":"2014-04","completion":"2014-05","firstPosted":"2013-06-10","resultsPosted":"2016-01-14","lastUpdate":"2016-01-14"},"enrollment":209,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing-Remitting Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"GA 20 mg/mL","otherNames":["Glatiramer Acetate","Copaxone®"]},{"type":"DRUG","name":"GA 40 mg/mL","otherNames":["Glatiramer Acetate","Copaxone®"]}],"arms":[{"label":"GA 20 mg/mL every day","type":"ACTIVE_COMPARATOR"},{"label":"GA 40 mg/mL 3 times a week","type":"EXPERIMENTAL"}],"summary":"This is an open-label, randomized, multi-center, parallel-arm study to assess the safety and tolerability of a daily dose of Glatiramer Acetate (GA) 40 mg/mL three times a week (TIW) administered subcutaneously (SC) as compared to GA 20 mg/mL every day (QD) administered SC.","primaryOutcome":{"measure":"Adjusted Mean Estimates for Injection-Related Adverse Event Rate Per Year in the Core Period","timeFrame":"Day 1 to Month 4","effectByArm":[{"arm":"GA 20 mg/mL QD (Core); 40 mg/mL TIW (Extension)","deltaMin":70.403,"sd":11.995},{"arm":"GA 40 mg/mL TIW (Core and Extension)","deltaMin":35.275,"sd":7.248}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0006"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":35,"countries":["United States"]},"refs":{"pmids":["26195058"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":101},"commonTop":["Injection site pain","Injection site erythema","Injection site mass","Injection site swelling","Injection site pruritus"]}}